In Focus

  • GISAID Scientific Advisory Council Meeting
    Geneva, 22 February 2018

    The GISAID Scientific Advisory Council will convene a meeting of its members on 22 February 2018 in Geneva, following the WHO Vaccine Consultation Meeting.

  • GISAID-WHO Bioinformatics Training Workshop
    Madagascar, 22 - 23 March 2018

    During the 6th African Network for the Surveillance of Influenza (ANISE) in Antananarivo, GISAID and isirv - in collaboration with Institut Pasteur de Madagascar and the World Health Organization’s Global Influenza Programme (GIP), with support from United States Agency for International Development (USAID) - are holding a two-day training workshop on genetic sequence analysis of influenza viruses to provide training for monitoring sequence variation among influenza viruses in relation to surveillance of influenza epidemics and detection of resistance to influenza antiviral drugs.

    > Find out more

  • WHO is fully supportive of GISAID

    During the 1st GISAID Symposium hosted by the Federal Republic of Germany, Assistant Director General Dr. Keiji Fukuda expresses WHO's support for GISAID.

    "We have the development of critically important and technically advanced new platforms such as GISAID. This data sharing initiative provides an important option for sharing genetic sequence and epidemiological data.  WHO is fully supportive of GISAID and any other initiative which promotes sharing and access to information, in ways that are trustworthy, transparent, efficient and timely."

    > read more
    > Breaking Through Influenza Information Walls

  • CBD Study finds 'GISAID might provide useful lessons and insight to ABS discussions'

    A peer-reviewed fact-finding and scoping study on digital sequence information on genetic resources in the context of the Convention on Biological Diversity and the Nagoya Protocol, highlights key advantages of GISAID’s sharing mechanism and a fair and equitable benefit-sharing resulting from access to data.

    With the core principals of timely international sharing of health data for protecting populations against lethal infectious disease outbreaks and adherence to scientific etiquette of acknowledgement of the source of data has resulted in global trust and confidence in GISAID.  > read the full study

  • First study of GISAID shows how it is possible to encourage greater international sharing of data, despite numerous challenges that exist

    A research study by the University of Sussex finds that by developing a successful track-record in the field of influenza, GISAID is contributing to global health in at least five ways:

    (1) collating the most complete repository of high-quality influenza data in the world; (2) facilitating the rapid sharing of information during outbreaks; (3) supporting the World Health Organization's strain selection process for the seasonal flu vaccine; (4) developing mechanisms to resolve potential conflicts concerning the sharing of virus data; and (5) building greater trust with countries that are key to global pandemic preparedness. 

    read more 
    > Data, disease and diplomacy: GISAID's innovative contribution to global health

  • G20 Health Ministers recognize the importance of GISAID in regard to virus data sharing

    At the invitation of Germany, the first meeting of Health Ministers of the Group of Twenty leading industrialized and emerging economies (G20) took place in Berlin between 19-20 May 2017.

    Under the banner of “Together Today for a Healthy Tomorrow – Joint Commitment for Shaping Global Health”, the two-day meeting focused on combating global health hazards. In their Berlin Declaration, the G20 Health Ministers recognize the importance of the Global Initiative on Sharing All Influenza Data (GISAID).

    > read more
    > The Berlin Declaration of the G20 Health Ministers (2017)

  • Data Providers to receive synthetic HA constructs, reverse genetics viruses, and antisera from H5 consortium 

    A consortium of investigators, made up of researchers from the University of Cambridge, the University of Wisconsin at Madison, and the Erasmus Medical Center in Rotterdam makes use of data in GISAID to generate synthetic hemagglutinin constructs to produce recombinant H5 viruses and H5-specific ferret antisera, building antigenic maps to represent all H5 viruses that have circulated from 1997 to the present day, providing critical information to stakeholders around the globe, for example for the design of vaccines for humans or poultry.

    > Read more

  • Editorial Board affirms Open Access designation of GISAID

    re3data.org and DataCite, the world’s leading provider of digital object identifiers (DOI) for research data, affirmed the designation of access to GISAID's database and data as Open Access. A persistent link for this designation has been assigned to GISAID for citation purposes ().  

    GISAID satisfies all conditions of the definition for open access contributions of the Berlin Declaration on Open Access to Knowledge in the Sciences and Humanities, last but not least, due to GISAID's ability "to provide a mechanism to enforce proper attribution“ through its user identification procedures, validating terms of use and licenses.

    > http://doi.org/10.17616/R3Q59F
    > The Berlin Declaration on Open Access to Knowledge in the Sciences and Humanities (2003)

Public-Private Partnerships of the GISAID Initiative

The GISAID Initiative involves public-private-partnerships between the Initiative's administrative arm Freunde of GISAID e.V., a registered non-profit association, and governments of the Federal Republic of Germany, the official host of the GISAID platform and EpiFlu™ database, Singapore and the United States of America